Market News

Suanfarma - a specialised supplier of raw materials to the pharmaceutical industry - acquires a stake in the CDMO.

Will provide cGMP storage, local labelling, secondary packaging, comparator sourcing, handling and distribution of ambient and cold chain supplies to clinical site returns management.

Patent covers East Indian sandalwood oil-containing compositions that can be used to treat a variety of cancers.

The CDMO' investment will reinforce its expertise in opiate and synthetic drug development and production.

Is the first registration Dechra has achieved through Putney's development pipeline since it acquired the US-based business

Company has invested in semi-automated vacuum stopper equipment to generate prefilled syringe samples that can be used to screen and select components, complete compatibility studies, and conduct developmental stability studies.

“The Clear Your Head Medicine” is poised to lead the sinus category, offering clarity in a confusing allergy and cold aisle.

Chrono Therapeutics is developing a wearable transdermal drug delivery device offering a personalised behavioural support system that times nicotine delivery to when smokers have their strongest cravings.

Enhances viral safety while maintaining cell line productivity, protein quality.

Patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections.

The acquisition will generate a new and strong international microbial CMO, offering the complete services from process development to large-scale market supply.

Company's immuno-oncology and histology services have allowed clients' go/no-go decisions to be made earlier in the drug development process and ultimately reduce clinical attrition.

Patent and market authorization for human hyperacute serum product.

The BlueWind VIVENDI System is a wireless, battery-less neurostimulator which is 90% smaller than typical neurostimulators in the market.

The Aerobika device demonstrated a clinically-significant reduction in exacerbations in as little as 30 days of treatment, when used as an add-on to usual COPD medications.

To be Commercialized in Portugal and Ireland as Vitaros and in Poland as Vytaros.

2016 report topics include 3D printing, FDA quality metrics, contract services, pharma growth in China and India, and generic licensing.

The plant will continue to manufacture critical AstraZeneca pharmaceutical products on a contract basis.

Webinar will focus on the nasal drug delivery route in the treatment of central nervous system diseases.

The investment includes the installation of new multi-purpose reactors and upgrading of the control room within an existing plant on site.

Acquisition of RetroSense Therapeutics adds global rights to RST-001, a novel gene therapy approach for the potential treatment of Retinitis Pigmentosa.

A range of best-in-class solutions that drive productivity in the laboratory.

First Generic and clinically validated product for Multiple Sclerosis in Europe.

Generic equivalents to Razadyne.

Compact device capable of delivering high viscosity drugs including some of the newest biologics.

Therapeutic equivalent generic version of GSK's Wellbutrin SR.

US Patent and Trademark Office has ruled in favour of Mylan in its inter partes review proceeding.

Unique product and service portfolio extensively covers all steps from cell line development to commercial manufacturing processes.

The CDMO has expanded its capabilities with a new automatic vial filling line to meet increased demand.

The artificial nose can sniff out Pulmonary Arterial Hypertension on a person’s breath as the disease alters its signature.

The new facility will be the global Center of Excellence for Extractable Studies and Impurities Profiling, as a hub across the global network of laboratories.

Company will discuss common tabletting problems such as increasing output without capital expenditure, eliminating sticking and abrasion, minimising headwear and corrosion, all of which can be done through innovative means.

The agreement comprises technology transfer and commercial manufacturing of the products Entocort and Asacol.

With the addition of Agrippal and Fluad, PaxVax is building a robust portfolio of vaccines for the Swiss market.

Merger creates global leader in life science and advanced technology materials.

World’s first wireless, miniature implantable device hailed by doctors and patients as a long-term therapy breakthrough.

Informing the pharmaceutical drug development, manufacturing and commercialization industry.

List price of $300 per generic EpiPen two-pack carton, which represents a discount of more than 50% to the Mylan list price.

Xiidra is the only prescription eye drop approved by the FDA for the treatment of both signs and symptoms of dry eye disease.

Companies will collaborate to develop and commercialize four generic products - two CNS stimulants and two beta blockers.

Patent expected to be valid until 2032, once granted.

Potential for 100 mg blister cards being packaged in 200 mg containers.

Approximately 40,000 women in England seek hospital treatment for uterine fibroids every year.

New Webinar Hosted by Xtalks.

USPTO has ruled in favour of Mylan in its inter partes review proceeding and found all claims of two related Copaxone 40 mg/mL patents to be unpatentable.

The investment will see the introduction of a new lyophiliser for vials, increasing the facility’s capacity by approximately 20%.

Mylan doubling the eligibility for patient assistance, effectively eliminating out-of-pocket expense for uninsured and under-insured patients.

A number of pipeline T2DM therapeutics are anticipated to be significant contributors to market growth over the forecast period, with some even expected to reach blockbuster status.

Patient centricity, combination products, packaging innovation and biotherapeutics showing promise at the forefront of the industry’s development.

Will invest more than $80 million.

Recall due to presence of iron oxide particulate matter.

Under this partnership, BioTechnique will manufacture a commercially available vaccine product in a new, shelf-stable dosage form.

Used by eight out of the top 10 global pharmaceutical companies, ERM’s newest version includes the industry’s first triple federated search engine.

Recognized for innovation and advancements in cell therapy.

Topics covered include why, how and when instruments should be calibrated to ensure they are delivering accurate measurement.

Despite the restoration and maintenance of sinus rhythm being a common practice in the management of atrial fibrillation, the available antiarrhythmic drugs are of modest efficacy and have unfavorable safety profiles.

A component of Regeneron's Rapid Response program, which is also targeting Zika and Ebola.

Medivation agrees to transaction valued at $81.50 per Medivation share in cash, for a total enterprise value of approximately $14 billion.

GBI Research’s analyses identifies 129 first-in-class programs in active development.

Expansion is the result of the demand for the company's automation, process control and serialization technology services.

Products now approved in seven countries.

Cut in staff due to failed clinical study of CRLX101.

Partner to fully fund development of new production routes for a family of APIs.

Patent broadly covers pharmaceutical compositions for microbiome therapeutics based on bacterial consortia.

Product is therapeutically equivalent to Spectrus Pharmaceuticals' reference listed drug Fusilev Injection.

The vast reforms seen throughout Turkey’s pharmaceutical market create a number of opportunities for pharmaceutical manufacturers.

Transmembrane conductance regulator modulating therapies - of which there are currently only two and both are developed by Vertex - are set to have a substantial clinical and commercial impact.

Falling stock markets, political uncertainty and continued global economic weakness all contributed to a mixed first half, says market intelligence firm, Evaluate.

Cresemba (isavuconazole) is an injectable and oral anti-fungal product.

State-of-the-art pharma manufacturing campus will be a showcase for the company and the production of injectable generics.

Cytokine and cytokine receptors, as well as protein kinases, largely dominate.

Acquisition will provide Piramal with HPAPI capabilities in North America.

Trend could jeopardize the affordability of life-saving orphan drugs for patients with rare diseases and conditions.

The VOYAGER II is the only commercially available pipette range where the tip spacing can be changed electronically,

Trial will look to explore the benefit of combining CV301 with Opdivo in patients with previously treated non-small cell lung cancer.

New product range includes chemically-defined, serum-free media, to increase productivity of viral vectors and recombinant proteins in suspension cultures.

Strengthens Lonza’s specialty nutritional ingredients portfolio.

New plant aims to double SRF’s capacity for chloromethanes to 80,000 tonnes per annum.

Preparations underway for the first human trials involving patients with antibiotic resistant lung infections.

Acquisition adds global ights to non-invasive ocular ring in development for glaucoma and other eye conditions.

Growth attributed to launches of the first proprotein convertase subtilisin/kexin type 9 (PCSK9 inhibitors), Repatha and Praluent by 2016, the launch of ETC-1002 by 2021, and increases in the global prevalence of ACS.

New regulations speeding up growth with exports to Japan targeted.

CPHI Pharma Awards’ panel doubles in size and welcomes top experts from around the world.

Expanded partnership provides capacity and cost structure supporting Celsion's global commercial strategy for GEN-1.

Expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid APIs.

The Ultravap Levante will appeal to the budget-conscious laboratory who may wish to automate their sample dry-down bottleneck in the future.

Angiogenesis modulators and gene therapies to boost overall revenue within the forecast period.

Bioverativ will focus on accelerating innovation for people living with hemophilia and other blood disorders.

Cherwell to offer expert insight in environmental monitoring and process validation to both NHS and industrial pharmaceutical manufacturers.

Vonvendi is a significant advancement for the treatment of adults with von Willebrand disease.

SkinJect Microneedle Patch to deliver drug to treat and immunize skin cancer patients.

Through this partnership, the academic institutions in the Consortium will have access to Charles River’s early discovery and drug development resources and services to accelerate their early-stage drug development processes.

The portfolio is a mix of six ANDAs pending approval, one approved ANDA and one ANDA with tentative approval, and comprises complex generic products across diverse dosage forms.

Opdivo (nivolumab) now recommended to treat Scottish NHS patients with advanced skin cancer.

Valeant obtains the rights to develop and commercialise NER1006 Powder for Oral Solution.

With the addition of Meda, Mylan now has six $1 billion therapeutic franchises.

Natco receives approval for generic Tamiflu.

Fully automated data transfer improves diabetes management.

Another Rx-to-OTC Switch from GSK Consumer Healthcare to help allergy sufferers find more complete relief.

AB-PA01 designed to broadly target both CF and non-CF Pseudomonas isolates and potentially eradicate the infection instead of merely keeping it at bay.

First US Patent issued to Vaxil since the company began developing its immunotherapies 10 years ago.

Subsidiary will be renamed Avara Pharmaceutical Technologies.

Increase will be driven by the growing use of recently approved and emerging branded T2DM therapeutics, in favour of lower-cost generic products, says GBI Research.

Continues Allergan's evolution into focused brand growth pharma leader.

Companies to pursue "off-the-shelf" cellular therapies in oncology.

Sale advances company's evolution into a focused branded growth pharma leader.

Acquisition combines Bamboo’s gene therapy portfolio, advanced vector design, and production technologies and capabilities with Pfizer’s global scale, research, development and commercialization experience.

People with radioiodine refractory differentiated thyroid cancer are overlooked as Lenvima is not scheduled for evaluation by NICE or the new Cancer Drugs Fund.

Steady growth will be driven by the uptake of novel oral anticoagulants, which represent important advances over warfarin, a cheap and established anticoagulant, says GlobalData.

Includes scale-up and GMP manufacturing of drugs in late-stage development.

Reduction is designed to reduce operating expenses while the company conducts a comprehensive evaluation of strategic options for galeterone and its pipeline.

If approved, SUN-101/eFlow will be the first nebulized long-acting muscarinic antagonist (LAMA) for the long-term, maintenance treatment of airflow obstruction in patients with COPD.

The portfolio of products will be marketed by Xantis Pharma throughout Central and Eastern Europe.

Adlyxin is approved as Lyxumia in more than 60 countries.

Enzyme developed with CodeEvolver technology for preclinical therapeutics program exceeds agreement requirements.

GSK accused of patent infringement.

Cytokinetics to receive $65 million in upfront payments and $30 million in additional sponsored R&D; potential for more than $100 million in payments associated with the exercise of the option.

Company's ND0701 formulation intended for chronic therapy of Parkinson's disease and is developed for continuous subcutaneous administration by a small, low-volume, disposable patch-pump.

Investment in advanced manufacturing of new respiratory and biopharmaceuticals portfolio.